Moshe Sade-Feldman, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myeloid Cells | 8 | 2021 | 810 | 1.040 |
Why?
|
Melanoma | 11 | 2022 | 5511 | 0.860 |
Why?
|
Neutrophils | 3 | 2023 | 3721 | 0.550 |
Why?
|
HLA-DR Antigens | 1 | 2016 | 645 | 0.480 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2024 | 4479 | 0.420 |
Why?
|
Immunotherapy | 7 | 2024 | 4446 | 0.410 |
Why?
|
Antigen Presentation | 1 | 2017 | 1284 | 0.410 |
Why?
|
Sepsis | 2 | 2023 | 2593 | 0.400 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2023 | 5172 | 0.350 |
Why?
|
Tumor Microenvironment | 9 | 2024 | 3590 | 0.270 |
Why?
|
Inflammation | 7 | 2015 | 10637 | 0.250 |
Why?
|
Chemokine CXCL9 | 1 | 2023 | 132 | 0.230 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2013 | 4424 | 0.210 |
Why?
|
Osteopontin | 1 | 2023 | 294 | 0.200 |
Why?
|
Viremia | 2 | 2022 | 736 | 0.200 |
Why?
|
Sterol Regulatory Element Binding Protein 2 | 1 | 2020 | 52 | 0.190 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9274 | 0.180 |
Why?
|
Cell Polarity | 1 | 2023 | 645 | 0.180 |
Why?
|
Sequence Analysis, RNA | 3 | 2023 | 2012 | 0.180 |
Why?
|
Cross Reactions | 1 | 2021 | 841 | 0.170 |
Why?
|
Transferrin | 1 | 2020 | 295 | 0.170 |
Why?
|
Immune Evasion | 1 | 2023 | 360 | 0.170 |
Why?
|
Endothelium | 1 | 2022 | 778 | 0.170 |
Why?
|
Pulmonary Alveoli | 1 | 2022 | 675 | 0.170 |
Why?
|
Lipogenesis | 1 | 2020 | 212 | 0.170 |
Why?
|
Immunoglobulin A | 1 | 2022 | 995 | 0.160 |
Why?
|
Mice, Inbred C57BL | 7 | 2021 | 21833 | 0.160 |
Why?
|
T Cell Transcription Factor 1 | 1 | 2018 | 49 | 0.160 |
Why?
|
Mice, Inbred BALB C | 3 | 2018 | 6386 | 0.160 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1038 | 0.160 |
Why?
|
Head and Neck Neoplasms | 2 | 2023 | 2736 | 0.160 |
Why?
|
Melanoma, Experimental | 1 | 2021 | 561 | 0.150 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2022 | 388 | 0.150 |
Why?
|
Substrate Specificity | 1 | 2021 | 1802 | 0.150 |
Why?
|
Immunity, Humoral | 1 | 2021 | 598 | 0.150 |
Why?
|
beta 2-Microglobulin | 1 | 2017 | 315 | 0.140 |
Why?
|
Glycolysis | 1 | 2021 | 829 | 0.140 |
Why?
|
T-Lymphocytes | 6 | 2020 | 10183 | 0.140 |
Why?
|
Receptors, Immunologic | 2 | 2020 | 1423 | 0.140 |
Why?
|
Cell Differentiation | 2 | 2014 | 11486 | 0.140 |
Why?
|
Immunoglobulin G | 2 | 2022 | 4561 | 0.140 |
Why?
|
Sorting Nexins | 1 | 2015 | 23 | 0.140 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1782 | 0.140 |
Why?
|
Apyrase | 1 | 2018 | 364 | 0.140 |
Why?
|
Mice, Knockout | 5 | 2021 | 14561 | 0.130 |
Why?
|
Alternative Splicing | 1 | 2021 | 1117 | 0.130 |
Why?
|
Loss of Heterozygosity | 1 | 2017 | 684 | 0.130 |
Why?
|
Macrophages | 2 | 2023 | 5660 | 0.130 |
Why?
|
Leukocytes | 1 | 2023 | 2045 | 0.120 |
Why?
|
Hepatitis C, Chronic | 1 | 2023 | 1031 | 0.120 |
Why?
|
Antigens, Neoplasm | 1 | 2022 | 1988 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2014 | 286 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 934 | 0.120 |
Why?
|
Phenotype | 5 | 2022 | 16367 | 0.110 |
Why?
|
Neoplastic Stem Cells | 1 | 2021 | 1376 | 0.110 |
Why?
|
Calgranulin A | 1 | 2013 | 79 | 0.110 |
Why?
|
Hepatitis C | 1 | 2023 | 1591 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2021 | 2540 | 0.110 |
Why?
|
Calgranulin B | 1 | 2013 | 84 | 0.110 |
Why?
|
Neoplasms, Experimental | 1 | 2017 | 1276 | 0.100 |
Why?
|
Point Mutation | 1 | 2017 | 1624 | 0.100 |
Why?
|
Base Sequence | 1 | 2023 | 12797 | 0.100 |
Why?
|
Cell Line, Tumor | 4 | 2022 | 16690 | 0.100 |
Why?
|
Humans | 31 | 2024 | 744366 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4851 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2013 | 595 | 0.090 |
Why?
|
Immunocompromised Host | 1 | 2015 | 847 | 0.090 |
Why?
|
Single-Cell Analysis | 4 | 2021 | 2182 | 0.090 |
Why?
|
B-Lymphocytes | 2 | 2020 | 4666 | 0.090 |
Why?
|
Fluorouracil | 1 | 2014 | 1619 | 0.090 |
Why?
|
Immunoblotting | 1 | 2013 | 1683 | 0.090 |
Why?
|
Mice | 10 | 2021 | 81201 | 0.090 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2022 | 4386 | 0.090 |
Why?
|
Prognosis | 6 | 2023 | 29060 | 0.080 |
Why?
|
Skin Neoplasms | 2 | 2022 | 5692 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13104 | 0.080 |
Why?
|
Membrane Glycoproteins | 1 | 2019 | 3771 | 0.080 |
Why?
|
Animals | 12 | 2021 | 168768 | 0.080 |
Why?
|
Antigens, CD | 1 | 2018 | 4026 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 1284 | 0.080 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2242 | 0.070 |
Why?
|
Disease Progression | 3 | 2021 | 13286 | 0.070 |
Why?
|
Chemokines | 2 | 2024 | 970 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4751 | 0.060 |
Why?
|
Cells, Cultured | 3 | 2020 | 19233 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3143 | 0.060 |
Why?
|
Killer Cells, Natural | 1 | 2013 | 2133 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2019 | 3524 | 0.060 |
Why?
|
Chronic Disease | 3 | 2013 | 9145 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5445 | 0.060 |
Why?
|
Tumor Necrosis Factors | 1 | 2023 | 109 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2012 | 2259 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 2282 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2013 | 5974 | 0.050 |
Why?
|
STAT Transcription Factors | 1 | 2023 | 182 | 0.050 |
Why?
|
Coronavirus OC43, Human | 1 | 2021 | 18 | 0.050 |
Why?
|
Neoplasms | 3 | 2019 | 21696 | 0.050 |
Why?
|
Janus Kinases | 1 | 2023 | 244 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11031 | 0.050 |
Why?
|
Spheroids, Cellular | 1 | 2023 | 351 | 0.050 |
Why?
|
Pentose Phosphate Pathway | 1 | 2021 | 124 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3554 | 0.040 |
Why?
|
Dendritic Cells, Follicular | 1 | 2020 | 53 | 0.040 |
Why?
|
Immunoglobulin Class Switching | 1 | 2021 | 291 | 0.040 |
Why?
|
Gene Expression | 1 | 2013 | 7798 | 0.040 |
Why?
|
Phthalazines | 1 | 2022 | 363 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 928 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2021 | 743 | 0.040 |
Why?
|
Lymphocyte Activation | 2 | 2021 | 5524 | 0.040 |
Why?
|
Complementarity Determining Regions | 1 | 2019 | 149 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2012 | 2988 | 0.040 |
Why?
|
Antigen-Presenting Cells | 1 | 2022 | 973 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 8432 | 0.040 |
Why?
|
Glutathione | 1 | 2021 | 590 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 2015 | 6773 | 0.040 |
Why?
|
Sirtuins | 1 | 2021 | 323 | 0.040 |
Why?
|
RNA, Neoplasm | 1 | 2021 | 769 | 0.040 |
Why?
|
Female | 9 | 2022 | 380193 | 0.040 |
Why?
|
Receptors, Fc | 1 | 2021 | 541 | 0.040 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2022 | 612 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 758 | 0.040 |
Why?
|
Virus Internalization | 1 | 2021 | 502 | 0.040 |
Why?
|
Organoids | 1 | 2023 | 701 | 0.040 |
Why?
|
HLA Antigens | 1 | 2022 | 1382 | 0.030 |
Why?
|
Clone Cells | 1 | 2020 | 1692 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1656 | 0.030 |
Why?
|
Hepacivirus | 1 | 2023 | 1379 | 0.030 |
Why?
|
Leishmania donovani | 1 | 2015 | 65 | 0.030 |
Why?
|
DNA Replication | 1 | 2022 | 1399 | 0.030 |
Why?
|
Leishmaniasis, Visceral | 1 | 2015 | 94 | 0.030 |
Why?
|
Mice, Inbred DBA | 1 | 2015 | 642 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6476 | 0.030 |
Why?
|
Mice, Nude | 1 | 2021 | 3689 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2023 | 3207 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2022 | 6313 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2019 | 9735 | 0.030 |
Why?
|
Immunologic Memory | 1 | 2020 | 1348 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2014 | 408 | 0.030 |
Why?
|
Antioxidants | 1 | 2021 | 1659 | 0.030 |
Why?
|
Hepatitis | 1 | 2014 | 227 | 0.030 |
Why?
|
Leucovorin | 1 | 2014 | 628 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2204 | 0.030 |
Why?
|
DNA Damage | 1 | 2022 | 2432 | 0.030 |
Why?
|
Cancer Vaccines | 1 | 2019 | 1023 | 0.030 |
Why?
|
Middle Aged | 4 | 2022 | 213390 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2749 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2021 | 4208 | 0.030 |
Why?
|
Piperazines | 1 | 2022 | 2488 | 0.020 |
Why?
|
Granulocytes | 1 | 2013 | 548 | 0.020 |
Why?
|
Proteome | 1 | 2021 | 1798 | 0.020 |
Why?
|
Camptothecin | 1 | 2014 | 576 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2012 | 220 | 0.020 |
Why?
|
Survivors | 1 | 2021 | 2291 | 0.020 |
Why?
|
Antibodies | 1 | 2019 | 2460 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3177 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2569 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 11726 | 0.020 |
Why?
|
Th1 Cells | 1 | 2015 | 1057 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 2987 | 0.020 |
Why?
|
Th2 Cells | 1 | 2015 | 1061 | 0.020 |
Why?
|
Immunosuppressive Agents | 2 | 2013 | 4153 | 0.020 |
Why?
|
Male | 5 | 2022 | 350115 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2015 | 10483 | 0.020 |
Why?
|
Tumor Escape | 1 | 2012 | 350 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 40559 | 0.020 |
Why?
|
Apoptosis | 2 | 2014 | 9724 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7294 | 0.020 |
Why?
|
Proteomics | 1 | 2021 | 3638 | 0.020 |
Why?
|
Hepatocytes | 1 | 2014 | 1211 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2014 | 3848 | 0.020 |
Why?
|
Down-Regulation | 1 | 2014 | 3001 | 0.020 |
Why?
|
Adult | 4 | 2022 | 214052 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2015 | 18034 | 0.020 |
Why?
|
Models, Biological | 1 | 2021 | 9584 | 0.020 |
Why?
|
Monocytes | 1 | 2013 | 2596 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15535 | 0.010 |
Why?
|
Phosphorylation | 1 | 2014 | 8436 | 0.010 |
Why?
|
Child | 2 | 2022 | 77709 | 0.010 |
Why?
|
Aged | 3 | 2022 | 163288 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1888 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 12073 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18373 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2014 | 2962 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2014 | 2214 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8385 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2725 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10943 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 2015 | 3712 | 0.010 |
Why?
|
Liver | 1 | 2014 | 7475 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2014 | 4253 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23404 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 21748 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 57776 | 0.010 |
Why?
|
Mutation | 1 | 2020 | 29786 | 0.010 |
Why?
|
Young Adult | 1 | 2021 | 56429 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11525 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 85779 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13693 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 15160 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2014 | 63107 | 0.000 |
Why?
|